IP Finance Blog -- A Good Idea to Cut Public Funding for R&D? Doesn't Look Like It.

[Mike Mireles]

Wednesday, 8 October 2025

A Good Idea to Cut Public Funding for R&D? Doesn't Look Like It.

David Rotman has authored an excellent article titled, “How to Measure the Returns on R&D Spending: Forget the Glorious Successes of Past Breakthroughs—the Real Justification for Research Investment is What We Get for Our Money. Here’s What Economists Say” in the MIT Technology Review.  The article does a nice job explaining recent research concerning public funding of R&D and the return on investment to the public.  The article notes that many questions are not answered.  The article is available, here. 

Posted by Mike Mireles at 22:58:00 No comments:   

Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

Labels: Bayh-Dole Act, commercialization, NAS, National Academy of Sciences, National Institutes of Health, NIH, patents, public funding, R&D spending, return on investment, Trade secrets